Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Patent
1997-11-07
1999-11-30
Saunders, David
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
4241331, 4241351, 4241461, 5303873, 53038825, 53038826, A61K 39395
Patent
active
059938153
ABSTRACT:
Methods and products for the treatment of a disorder characterized by the cleavage of a C-terminal lysine or arginine from an intact peptide are provided. In the methods of the invention a peptide that inhibits the activation of thrombin-activatable fibrinolysis inhibitor (TAFI) is administered in an effective amount and in a pharmaceutically acceptable carrier to a subject having a disorder characterized by the cleavage of a C-terminal lysine or arginine from an intact peptide. The compositions are pharmaceutical compositions of peptides that inhibit the activation of TAFI. Also provided is a monoclonal antibody that binds TAFI zymogen but that does not bind to active TAFI and inhibits the activation of TAFI.
REFERENCES:
patent: 5094942 (1992-03-01), Hashizuma et al.
patent: 5206161 (1993-04-01), Drayna et al.
patent: 5364934 (1994-11-01), Drayna et al.
patent: 5474901 (1995-12-01), Drayna et al.
Rowland, M. and Tozer, TN. Clinical Pharmacokinetics: Concepts and Applications, Second Edition. Lea & Febiger, Philadelphia, pp. 9, 10, 54, 55, 132-134, 1989.
Khan, AR and James, MNG. Moleuclar mechanisms for the conversion of zymogens to active proteolytic enzymes. Protein Sci. &:815-836, 1998.
Bajzer L., et al., The fibrinolytic effect of activated protein C (APC) in plasma is specifically attributed to its ability to inhibit the activation of TAFI. Blood. 86:(10) Suppl. 1, Abstract No. 1420, Nov. 1995.
Bajzar, L., et al., Purification and characterization of TAFI, a thrombin-activatable inhibitor. J. Biol. Chem. 270(24):14477-14484, Jun. 1995.
Sheth et al., "Administration of a Humanized Monoclonal Antibody to Factor IX in Healthy Volunteers," Blood 92 (10) p. 362a (1998), Abstract #1491 only.
Blackburn et al., "Anti-factor IX Monoclonal Antibody, BC2, Is a Potent Antithrombotic Agent," Blood 90 (10) pp. 424a-425a (1997), Abstract #1885 only.
Blackburn et al., "Anti-factor IX Monoclonal Antibody: Extended Duration of Therapeutic Protection for Arterial Thrombosis," Blood 92 (10) p. 670a (1998), Abstract #2761 only.
Von dem Borne, P., et al., "Thrombin-Mediated Activiation of factor XI Results in a TAFI or Carboxy-peptidase B Dependent Inhibition", Blood 88, (1996), 10 Suppl. 1 part 1-2, 469A.
Church, W., et al., "Functional effect of monoclonal antibodies . . . ", J Cell Biochem Suppl 15 (Part E), (Mar. 16, 1991), p. 131.
Jenny, R., et al., "Immunochemical techniques for studying coagulation proteins" Methods Enzymol. (1993), 222:400-416.
Sangrar, W., et al., "Antifibrinolytic Effect of Recombinant . . . ", Biochemistry, (1995), 34:15:5151-5157.
Von dem Borne, P., et al., "Thrombin-Mediated Activiation of factor XI Results in . . . " J Clin Invest. (May 15, 1997), 99:10:2323-2327.
Hoogendoorn, H., et al., "A qualitative and quantitative analysis of the activation . . . ", Blood, (Jun. 1, 1990), 75:11:2164-2171.
Taylor, F., et al., "Anticoagulant and fibrinolytic activities . . . ", Blood, (Apr. 1, 1992), 79:7:1720-1728.
Cote, H., et al., "Functional characterization of recombinant humna . . . " J Biol. Chem., (Mar. 7, 1997) 272:10:6194-6200.
Bajzar, L., et al., "An antifibrinolytic mechanism describing the prothrombotic effect", J. Biol. Chem. (1996), 271:38:22949-22952.
Bajzar, L., et al., "TAFI, or plasma procarboxypeptidase B, couples . . . ", J. Biol. Chem., (1996), 271:38: 16603-16608.
Fredenburgh, J., et al., "Lys-plasminogen is a significant intermediate . . . ", J Biol Chem, (Dec. 25, 1992) 267:36:26150-26156.
Boffa, M., et al., Characterization of recombinant TAFI expressed . . . Abstract of the International Congress on Fibrinolysis and Thrombolysis, Barcelona, Spain, Jun. 24-28 1996--Abstract.
Neisheim, M., et al., "Thrombin, Thrombomodulin and . . . ", Thrombosis and Haemostasis, (1997) 78:1:386-391.
Felez, J., et al., "Competition Between Plasminogen and Tissue . . . ", Blood, (1993), 82:8:2433-2441.
Mosesson, M., et al., "The assembly and structure of the fibrin clot", Nouv Rev Fr Hematol, (1992) 34:11-16.
Haber, F. et al., "Antibody-Targeted Throbolytic Agents", Japanese Circulation Journal, (1990) 54:345-353.
Takahashi, Hoyu, "Citculating Thrombomodulin as a Novel . . . " American J Hematology, (1992) 41:32-39.
Pixley, R., et al., "The Contact System Contributes to hypotension . . . ", J. Clin. Invest., (1993) 91:61-68.
Horrevoets A., et al., "The Activation-resistant Conformation of Recombinant Human Plasminogen . . . " J. Biological Chemistry, (1995), 270:26:15770-15776.
Stevens, W., et al., "Calcium Ion Modulation of Meizothrombin . . . ", J. Biological Chemistry, (1996) 271:14:8062-8067.
Bajzar, L., et al., "The Provibrinolysis Effect of Activated Protein . . . ", Blood, (1996), 88:001-008.
Bajzar, L., et al., "The Activated Protein C-mediated Enhancement of Tissue-type", J. Biological Chemistry, (1990), 265:28:16948-16954.
Bajzar, L., et al., "The Effect of Activated Protein C on Fibrinolysis in . . . ", J. Biological Chemistry, (1993), 268:12:8608-8616.
Pryzdial, E., et al., "Prothrombinase Components Can Accelerate . . . ", J. Biological Chemistry, (1995), 270:30:17871-17877.
Bokisch, V., et al., "Anaphylatoxin Inactivator of Human Plasma: Its Isolation and . . . ", J Clin, Invest. (1970), 49:2427-2436.
Hesselvik, J., et al., "Protein C, Protein S and C4b-Binding . . . ", Thrombosis and Haemostasis, (1991) 65:2:126-129.
Keyt, B., et al., "The Carboxyl-terminal Domain (111-165) of Vascular Endothelial . . . ", J. Biological Chemistry, (1996), 271:13:7788-7795.
Durie, F., "Collagen-Induced Arthritis as a Model of Rheumatoid Arthritis", Clinical Immunology and Immunopathology, (1994), 73:1:11-18.
Fava, R., et al., "Vascular Permeability Factor/Endothelial Growth . . . ", J. Exp. Med., (1994), 180:341-346.
Eaton, D., et al., "Isolation, Molecular Cloning, and Partial Characterization of a Novel . . . ", J. Biological Chem., (1991), 266:32:21833-21838.
Redlitz, A., et al., "Inducible Carboxypeptidase Activity", Circulation, (1996), 93:7:1328-1330.
Delk, A., et al., "Radioimmunoassay of Active Pancreatic Enzymes in Sera . . . ", Clin Chem., (1985), 31:8:1294-1300.
Valnickova, Z., et al., "Activated Human Plasma Carboxypeptidase . . . " J. Biological Chem., (1996), 271:22:12937-12943.
Tan, A., et al., "Activation and Characterization of Procarboxypeptidase B . . . ", Biochemistry, (1995) 34:5811-5816.
Tang, L., et al., "Molecular Determinants of Acute Inflammatory . . . ", J. Clin. Invest., (1996), 97:5:1329-1334.
Esmon, C., et al., "Thrombomodulin as a model of molecular . . . ", The Faseb Journal, (1995) 9:946-955.
Conway, E., et al., "Biologically Active Thrombomodulin Is . . . Arthritis", Blood, (1993) 81:3:726-733.
Takano, S., et al., "Plasma Thrombomodulin in Health and Diseases", Blood, (1990), 76:10:2024-2029.
Bajzar Laszlo S.
Church William R.
Nesheim Michael E.
Saunders David
Tung Mary Beth
University of Vermont
LandOfFree
Methods and compositions for inhibiting the activation of thromb does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for inhibiting the activation of thromb, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for inhibiting the activation of thromb will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1668108